ReviewThe American journal of medicine2012
Hypertension and chronic kidney disease progression: why the suboptimal outcomes?
Review in The American journal of medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Pooled it
- Early mineralocorticoid receptor antagonism for end-organ protection in hypertension: Implications for disparities and rethinking the timing paradigm.Dialogues in health · 2026Review
- To Compare Different Blood Pressure Measurement Techniques in Patients with Chronic Kidney Disease.Annals of African medicine · 2026Observational
- The difference between nocturnal dipping status and morning blood pressure surge for target organ damage in patients with chronic kidney disease.Journal of clinical hypertension (Greenwich, Conn.) · 2020Article
- Mechanisms of Synergistic Interactions of Diabetes and Hypertension in Chronic Kidney Disease: Role of Mitochondrial Dysfunction and ER Stress.Current hypertension reports · 2020Review
- BP Fluctuations and the Real-Time Dynamics of Renal Blood Flow Responses in Conscious Rats.Journal of the American Society of Nephrology : JASN · 2020Article
- Comparisons between different blood pressure measurement techniques in patients with chronic kidney disease.Kidney research and clinical practice · 2019Article
- Prognostic value of nighttime blood pressure load in Chinese patients with nondialysis chronic kidney disease.Journal of clinical hypertension (Greenwich, Conn.) · 2017Article
- Nocturnal Hypertension Correlates Better With Target Organ Damage in Patients With Chronic Kidney Disease than a Nondipping Pattern.Journal of clinical hypertension (Greenwich, Conn.) · 2015Article
- Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.Clinical research in cardiology : official journal of the German Cardiac Society · 2015Review
- High prevalence of isolated nocturnal hypertension in Chinese patients with chronic kidney disease.Journal of the American Heart Association · 2015Article
- Article
- Interpreting treatment-induced blood pressure reductions measured by ambulatory blood pressure monitoring.Journal of human hypertension · 2013Review
- Renal microvascular dysfunction, hypertension and CKD progression.Current opinion in nephrology and hypertension · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Current therapeutic interventions to retard the progression of chronic kidney disease have yielded disappointing outcomes despite adequate renin-angiotensin system blockade. The parameters to gauge the adequacy of blood pressure control need to be reassessed because clinic blood pressure constitutes a poor gauge of such control. The biologically relevant parameter for hypertensive target organ damage is total blood pressure burden, and reliance on isolated clinic blood pressure measurements per se does not accurately reflect the total blood pressure burden. This is particularly relevant to the population with chronic kidney disease in whom masked daytime or nocturnal hypertension and blood pressure lability are both widely prevalent and more difficult to control. Consequently, it is possible that the limited success currently being achieved in preventing or attenuating chronic kidney disease progression may be attributable in part to suboptimal 24-hour blood pressure control. Recent data and analyses also indicate that blood pressure variability, instability, episodic and nocturnal blood pressure elevations, and maximum systolic blood pressure may constitute additional strong predictors of the risk of target organ damage independently of mean systolic blood pressure. Accordingly, we suggest that future research should include the development of safe and effective strategies to achieve around-the-clock blood pressure control in addition to targeting mechanisms that reduce intrarenal blood pressure transmission or interrupt subsequent downstream pathways. Meanwhile, more aggressive use of patient education and home blood pressure monitoring with selection of longer-acting antihypertensive agents or nocturnal dosing should be considered to improve the current suboptimal results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.